Sativa Wellness - Name Change & Strategic Update
RNS Number : 8316X
Sativa Wellness Group Inc.
10 January 2022

10 January 2022

Sativa Wellness Group Inc.
("Sativa Wellness Group", or the "Company")


Name Change and Strategic Update

Sativa Wellness Group Inc announces change of name to Goodbody Health Inc and Clear Strategic Direction.

Sativa Wellness Group is pleased to announce a change of name to Goodbody Health Inc to align the parent company with its main brand name "Goodbody" and its trading subsidiaries "Goodbody Wellness Limited" and "Goodbody Botanicals Ltd". After significant feedback, the Board decided that the Goodbody brand using the proposition "Know More-Live Better" better promotes and reflects the Company's Strategic Direction as a Health and Wellness Company.

The Company's name change will be updated from 8.00 a.m. 13 January 2022 UK time on the Apex segment of the AQSE Growth Market ("AQSE") and on the Canadian Securities Exchange ("CSE") from market opening. The Company's shares will start trading under the new ticker "GBDY" on these exchanges from the same times.

The over the counter market ("OTC") in the United States and the Frankfurt Stock Exchange ("FSE") are expected to reflect this change soon after on their existing tickers as "484" for the FSE and "SCNFF" for the OTC.

The Company's web address will change as of 12 January 2022 to The information required pursuant to AQSE Growth Market Apex Rule 4.14 may be found at this address.

In 2020, the Company set up COVID testing clinics for travellers in response to the pandemic to supplement the existing wellness business. The success of these clinics continues to evolve into a range of wellness testing products and services in addition to the COVID testing and CBD products, with the realisation that customers are looking for wellness management as well as symptom diagnosis. This has yielded strong sales growth through the local independent pharmacies who are proactive in helping their community as well as directly to corporate and individual customers.

The need for radical investment and reform of diagnostic services was recognised at the time the NHS Long Term Plan was published in 2019.  The Covid-19 pandemic has further amplified the need for radical change in the provision of diagnostic services.

Currently, we offer a local level network of over 140 clinics nationwide, offering over 30 blood and PCR tests for at home or in clinic testing. We continue to provide CBD wellness products which are all submitted to the FSA as part of the novel food process as well as cannabinoid testing. By the end of 2022 we aim to offer 1,000 points of care for customers as well as an increased range of products and services.

Geremy Thomas, Executive Chairman, said: "Following the huge successes of 2021 in delivering health and wellness products and services, we are extremely keen to make sure all of our investors and other stakeholders understand the strategic direction of the company. The repositioning of our brand as Goodbody Health, combined with our key customer proposition of 'Know More - Live Better" better reflects our mission to be a major provider of wellness products across our ever-expanding distribution channels. We are very positive about the opportunities this will bring in 2022 and beyond."


For further information:

Marc Howells

Chief Executive Officer

Sativa Wellness Group Inc.

+44 (0) 20 7971 1255

Anne Tew

Chief Financial Officer

Sativa Wellness Group Inc.

+44 (0) 20 7971 1255




AQSE Corporate Adviser

Arden Partners plc

Antonio Bossi / George Morgan

+ 44 (0) 20 7614 5900 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.